NRX Pharmaceuticals, Inc.
NRXPNRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for central nervous system disorders, including suicidal depression, chronic pain, PTSD, and schizophrenia.
Earnings
Next report
Nov 13, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for central nervous system disorders, including suicidal depression, chronic pain, PTSD, and schizophrenia. The company utilizes a dual-track strategy of drug development and direct clinical service delivery through its majority-owned subsidiary, HOPE Therapeutics. Its core value proposition centers on enhancing neuroplasticity by modulating the NMDA receptor through proprietary formulations of ketamine and oral fixed-dose combinations.
A clinical-stage innovator leveraging Fast Track and Breakthrough Therapy designations to disrupt the generic ketamine market and establish a specialized psychiatric clinic network.
FAQ
- What is NRX Pharmaceuticals, Inc.'s market cap?
- NRX Pharmaceuticals, Inc. (NRXP) has a market capitalization of $149.8M and trades on NASDAQ.
- Who are NRX Pharmaceuticals, Inc.'s competitors?
- NRX Pharmaceuticals, Inc.'s key competitors include Johnson & Johnson, Cyclerion Therapeutics, Inc. Common Stock, Minerva Neurosciences, Inc, and others. These companies compete in similar markets and product categories.
- Who does NRX Pharmaceuticals, Inc. partner with?
- NRX Pharmaceuticals, Inc.'s notable partners include Nephron Pharmaceuticals, Inc., Alcami, Osmind, Inc., and others.
- What subsidiaries does NRX Pharmaceuticals, Inc. have?
- NRX Pharmaceuticals, Inc.'s subsidiaries include NeuroRx, Inc., HOPE Therapeutics, Inc., HTX Management Company, LLC, and others.
- Where is NRX Pharmaceuticals, Inc. headquartered?
- NRX Pharmaceuticals, Inc. is headquartered in United States of America. It has been publicly traded since 2021.